Treatment of CRS is not established, but tocilizumab, an anti-interleukin 6 receptor antibody, and steroid are currently recommended for CRS after CAR-T cell therapy.[8] In addition, one case report suggested the effectiveness of plasma exchange.[22] As for CRS induced by ICIs, three of four reported cases underwent treatments: high-dose steroid and tocilizumab[11], oral prednisolone[12], and steroid pulse therapy, MMF, and thrombomodulin[13], which improved each clinical symptom at least partially. Here, THBD is linked to congenital rubella syndrome.